Wave Life Sciences Ltd. will release interim data from the Phase 1 INLIGHT clinical trial evaluating WVE-007 for obesity treatment on December 8, 2025. WVE-007 is designed to silence the INHBE gene, a target associated with obesity. In preclinical models, WVE-007 showed potential for metabolic improvement by reducing adipocyte size and improving insulin sensitivity. The ongoing INLIGHT trial is assessing WVE-007’s safety, tolerability, and impact on body weight and composition. Wave Life Sciences focuses on developing RNA medicines to address various disorders, including obesity, alpha-1 antitrypsin deficiency, and Duchenne muscular dystrophy.

Read more at GlobeNewswire: Wave Life Sciences to Announce Interim Data from the Phase